MediWound (MDWD) Reports Q3 Loss, Misses Revenue Estimates

Core Insights - MediWound reported a quarterly loss of $0.24 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.81, representing an earnings surprise of +70.37% [1] - The company posted revenues of $5.43 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 15.52%, but showing an increase from $4.36 million year-over-year [2] - MediWound has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates two times in the same period [2] Financial Performance - The company experienced a loss of $0.98 per share in the same quarter last year, indicating improvement in financial performance [1] - The current consensus EPS estimate for the upcoming quarter is -$0.85 on revenues of $7.7 million, and for the current fiscal year, it is -$2.69 on revenues of $23.79 million [7] Market Position - MediWound shares have increased by approximately 0.3% since the beginning of the year, underperforming compared to the S&P 500's gain of 12.9% [3] - The Zacks Industry Rank for Medical - Drugs is in the top 29% of over 250 Zacks industries, indicating a favorable industry outlook [8] Future Outlook - The sustainability of MediWound's stock price movement will depend on management's commentary during the earnings call and future earnings expectations [3][4] - The estimate revisions trend for MediWound was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market [6]